172 related articles for article (PubMed ID: 7923174)
21. Uptake of mIBG and catecholamines in noradrenaline- and organic cation transporter-expressing cells: potential use of corticosterone for a preferred uptake in neuroblastoma- and pheochromocytoma cells.
Bayer M; Kuçi Z; Schömig E; Gründemann D; Dittmann H; Handgretinger R; Bruchelt G
Nucl Med Biol; 2009 Apr; 36(3):287-94. PubMed ID: 19324274
[TBL] [Abstract][Full Text] [Related]
22. Radiation-induced biologic bystander effect elicited in vitro by targeted radiopharmaceuticals labeled with alpha-, beta-, and auger electron-emitting radionuclides.
Boyd M; Ross SC; Dorrens J; Fullerton NE; Tan KW; Zalutsky MR; Mairs RJ
J Nucl Med; 2006 Jun; 47(6):1007-15. PubMed ID: 16741311
[TBL] [Abstract][Full Text] [Related]
23. Pharmacokinetics and efficacy of 131I-meta-iodobenzylguanidine in two neuroblastoma xenografts.
Gaze MN; Hamilton TG; Mairs RJ
Br J Radiol; 1994 Jun; 67(798):573-8. PubMed ID: 8032811
[TBL] [Abstract][Full Text] [Related]
24. [131I]meta-iodobenzylguanidine and topotecan combination treatment of tumors expressing the noradrenaline transporter.
McCluskey AG; Boyd M; Ross SC; Cosimo E; Clark AM; Angerson WJ; Gaze MN; Mairs RJ
Clin Cancer Res; 2005 Nov; 11(21):7929-37. PubMed ID: 16278418
[TBL] [Abstract][Full Text] [Related]
25. Validation of 4-[fluorine-18]fluoro-3-iodobenzylguanidine as a positron-emitting analog of MIBG.
Vaidyanathan G; Affleck DJ; Zalutsky MR
J Nucl Med; 1995 Apr; 36(4):644-50. PubMed ID: 7699460
[TBL] [Abstract][Full Text] [Related]
26. SIMS microscopy imaging of the intratumor biodistribution of metaiodobenzylguanidine in the human SK-N-SH neuroblastoma cell line xenografted into nude mice.
Clerc J; Halpern S; Fourré C; Omri F; Briançon C; Jeusset J; Fragu P
J Nucl Med; 1993 Sep; 34(9):1565-70. PubMed ID: 8355077
[TBL] [Abstract][Full Text] [Related]
27. No-carrier-added iodine-131-MIBG: evaluation of a therapeutic preparation.
Mairs RJ; Cunningham SH; Russell J; Armour A; Owens J; McKellar K; Gaze MN
J Nucl Med; 1995 Jun; 36(6):1088-95. PubMed ID: 7769433
[TBL] [Abstract][Full Text] [Related]
28. Comparison of radiohaloanalogues of meta-iodobenzylguanidine (MIBG) for a combined gene- and targeted radiotherapy approach to bladder carcinoma.
Fullerton NE; Boyd M; Ross SC; Pimlott SL; Babich J; Kirk D; Zalutsky MR; Mairs RJ
Med Chem; 2005 Nov; 1(6):611-8. PubMed ID: 16787344
[TBL] [Abstract][Full Text] [Related]
29. Uptake and storage of m-iodobenzylguanidine are frequent neuronal functions of human neuroblastoma cell lines.
Iavarone A; Lasorella A; Servidei T; Riccardi R; Mastrangelo R
Cancer Res; 1993 Jan; 53(2):304-9. PubMed ID: 8417824
[TBL] [Abstract][Full Text] [Related]
30. Noradrenaline transporter gene transfer for radiation cell kill by 131I meta-iodobenzylguanidine.
Boyd M; Cunningham SH; Brown MM; Mairs RJ; Wheldon TE
Gene Ther; 1999 Jun; 6(6):1147-52. PubMed ID: 10455418
[TBL] [Abstract][Full Text] [Related]
31. [(131)I] and [(125)I] metaiodobenzylguanidine therapy in macroscopic and microscopic tumors: a comparative study in SK-N-SH human neuroblastoma and PC12 rat pheochromocytoma xenografts.
Rutgers M; Buitenhuis CK; van der Valk MA; Hoefnagel CA; Voûte PA; Smets LA
Int J Cancer; 2000 Dec; 90(6):312-25. PubMed ID: 11180134
[TBL] [Abstract][Full Text] [Related]
32. A 4-methyl-substituted meta-iodobenzylguanidine analogue with prolonged retention in human neuroblastoma cells.
Vaidyanathan G; Welsh PC; Vitorello KC; Snyder S; Friedman HS; Zalutsky MR
Eur J Nucl Med Mol Imaging; 2004 Oct; 31(10):1362-70. PubMed ID: 15205923
[TBL] [Abstract][Full Text] [Related]
33. Meta-[123I]iodobenzylguanidine is selectively radiotoxic to neuroblastoma cells at concentrations that spare cells of haematopoietic lineage.
He Y; Das B; Baruchel S; Kumar P; Wiebe L; Reilly RM
Nucl Med Commun; 2004 Nov; 25(11):1125-30. PubMed ID: 15577592
[TBL] [Abstract][Full Text] [Related]
34. Adrenergic, cholinergic, and inactive human neuroblastoma cell lines with the action-potential Na+ ionophore.
West GJ; Uki J; Herschman HR; Seeger RC
Cancer Res; 1977 May; 37(5):1372-6. PubMed ID: 15722
[TBL] [Abstract][Full Text] [Related]
35. Meta-iodobenzylguanidine derivatives containing a second guanidine moiety.
Vaidyanathan G; Shankar S; Affleck DJ; Alston K; Norman J; Welsh P; LeGrand H; Zalutsky MR
Bioorg Med Chem; 2004 Apr; 12(7):1649-56. PubMed ID: 15028258
[TBL] [Abstract][Full Text] [Related]
36. HBO and the uptake and retention of [125I] MIBG in human platelets and two neuroendocrine cell lines.
Tytgat GA; Cornelissen J; Van den Brug M; Van Kuilenburg AB; Voute PA; Van der Kleij AJ; Van Gennip AH
Anticancer Res; 1997; 17(2A):1209-12. PubMed ID: 9137473
[TBL] [Abstract][Full Text] [Related]
37. No-carrier-added iodine-131-FIBG: evaluation of an MIBG analog.
Vaidyanathan G; Zhao XG; Strickland DK; Zalutsky MR
J Nucl Med; 1997 Feb; 38(2):330-4. PubMed ID: 9025764
[TBL] [Abstract][Full Text] [Related]
38. The cytotoxicity and microdosimetry of astatine-211-labeled chimeric monoclonal antibodies in human glioma and melanoma cells in vitro.
Larsen RH; Akabani G; Welsh P; Zalutsky MR
Radiat Res; 1998 Feb; 149(2):155-62. PubMed ID: 9457895
[TBL] [Abstract][Full Text] [Related]
39. 1-(m-[211At]astatobenzyl)guanidine: synthesis via astato demetalation and preliminary in vitro and in vivo evaluation.
Vaidyanathan G; Zalutsky MR
Bioconjug Chem; 1992; 3(6):499-503. PubMed ID: 1463779
[TBL] [Abstract][Full Text] [Related]
40. 131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
Gaze MN; Mairs RJ; Boyack SM; Wheldon TE; Barrett A
Br J Cancer; 1992 Dec; 66(6):1048-52. PubMed ID: 1457344
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
